Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension

BACKGROUND: Droxidopa is approved for adult patients with symptomatic neurogenic orthostatic hypotension (nOH); there is limited information regarding effects on symptoms, outcomes, and quality of life (QOL) beyond two weeks of treatment. OBJECTIVE: Examine the real‐world experience of patients taki...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mov Disord Clin Pract
Egile Nagusiak: François, Clément, Shibao, Cyndya A., Biaggioni, Italo, Duhig, Amy M., McLeod, Kim, Ogbonnaya, Augustina, Quillen, Apryl, Cannon, Joan, Padilla, Byron, Yue, Binglin, Orloski, Laurie, Kymes, Steven M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2019
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6417751/
https://ncbi.nlm.nih.gov/pubmed/30949555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12726
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak